Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus (Q38719567)
Jump to navigation
Jump to search
scientific article published on 24 January 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus |
scientific article published on 24 January 2017 |
Statements
1 reference
Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus (English)
1 reference
influenza A virus
1 reference
Fatemeh Fotouhi
1 reference
Mina Shaffifar
1 reference
Behrokh Farahmand
1 reference
Sadegh Shirian
1 reference
Mohsen Saeidi
1 reference
Alijan Tabarraei
1 reference
Ali Gorji
1 reference
Amir Ghaemi
1 reference
24 January 2017
1 reference
1 reference
162
1 reference
5
1 reference
1251-1260
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference